EMA Application withdrawn: Arikayce (amikacin sulfate) — Insmed Limited

View source ↗

Summary

The EMA withdrew the application for Arikayce (amikacin sulfate) by Insmed Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Infections

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

Status: Application withdrawn. Therapeutic area: Mycobacterium Infections. MAH: Insmed Limited. Decision date: 24/06/2016